A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, ...

With just the click of a button on your smartphone, you can order virtually anything and have it on your doorstep in one or ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

Approximately one in eight women in the U.S. will be diagnosed with breast cancer during their lifetime. Nearly 30 percent of women who are diagnosed with early-stage breast cancer will eventually ...

The development of Generative AI (Gen AI) in clinical trials has been likened to a progressive journey from infancy to maturity. As Gen AI reaches advanced stages, it also introduces risks such as ...

Growth hormone deficiency (GHD) is a rare disorder characterized by the insufficient production of growth hormone, which is essential for stimulating the growth of bones and other tissues. Children ...

Disagreements about budgets can delay or stall drug development. As the clinical research industry experiences unprecedented rises in costs, having the most current data available when creating and ...

Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its ...

No drug is free from risks, and no two human anatomies are completely identical (meaning different individuals can face different risks), but from a real-world patient perspective — anecdotally — the ...